Sorafenib, a VEGF inhibitor, is currently the only therapy option [3]. An article by Rong et al., reviewing 1,197 HCC lesions treated with cryoablation, was noted to have a complete response to therapy in 1,163 (96.1%) lesions with an overall complication rate of just 2.8%, with no treatment-related mortalities [15]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.